CANCER:

Esophageal Adenocarcinoma

Related cancers:

‹

Esophageal Cancer (150)

Esophageal Squamous Cell Carcinoma (64)

Esophageal Cancer (150)

Esophageal Squamous Cell Carcinoma (64)

›

PD-L1 expression PD-L1 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	PD-L1 expression PD-L1 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	nivolumab Sensitive: B - Late Trials ESMO-GI 2022 - 5 days (New B)	nivolumab Sensitive: B - Late Trials ESMO-GI 2022 - 5 days - (New B)
No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
HER-2 negative + PD-L1 expression HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	HER-2 negative + PD-L1 expression HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	ramucirumab Sensitive: A2 - Guideline	ramucirumab Sensitive: A2 - Guideline
HER-2 positive HER-2 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	HER-2 positive HER-2 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline	trastuzumab Sensitive: A2 - Guideline
HER-2 overexpression HER-2 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	HER-2 overexpression HER-2 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline	trastuzumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	PD-L1 expression PD-L1 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	FP Sensitive: A2 - Guideline	FP Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	FLOT Sensitive: A2 - Guideline	FLOT Sensitive: A2 - Guideline
No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	FOLFOX Sensitive: A2 - Guideline	FOLFOX Sensitive: A2 - Guideline
HER-2 overexpression HER-2 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	HER-2 overexpression HER-2 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	PD-L1 overexpression PD-L1 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	nivolumab Sensitive: B - Late Trials	nivolumab Sensitive: B - Late Trials
PD-L1 underexpression PD-L1 underexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	PD-L1 underexpression PD-L1 underexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	Immunotherapy Resistant: B - Late Trials	Immunotherapy Resistant: B - Late Trials
HER-2 positive HER-2 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	HER-2 positive HER-2 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	trastuzumab + pertuzumab Sensitive: C1 - Off-label	trastuzumab + pertuzumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	MSI-H/dMMR MSI-H/dMMR	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	nivolumab + ipilimumab Sensitive: C1 - Off-label	nivolumab + ipilimumab Sensitive: C1 - Off-label
CLDN18.2 expression CLDN18.2 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	CLDN18.2 expression CLDN18.2 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	IMAB362 Sensitive: C2 – Inclusion Criteria	IMAB362 Sensitive: C2 – Inclusion Criteria
HER-2 amplification HER-2 amplification	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	HER-2 amplification HER-2 amplification	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria	trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria
HER-2 positive HER-2 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	HER-2 positive HER-2 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	paclitaxel Resistant: C3 – Early Trials	paclitaxel Resistant: C3 – Early Trials
HER-2 positive HER-2 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	HER-2 positive HER-2 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	carboplatin Resistant: C3 – Early Trials	carboplatin Resistant: C3 – Early Trials
ARID1A mutation ARID1A mutation	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	ARID1A mutation ARID1A mutation	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
DKK1 overexpression DKK1 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	DKK1 overexpression DKK1 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials
DKK1 overexpression DKK1 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	DKK1 overexpression DKK1 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	DKN-01 Sensitive: C3 – Early Trials	DKN-01 Sensitive: C3 – Early Trials
GRB7 positive GRB7 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	GRB7 positive GRB7 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	trastuzumab + pertuzumab Sensitive: C3 – Early Trials	trastuzumab + pertuzumab Sensitive: C3 – Early Trials
HER-2 overexpression HER-2 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	HER-2 overexpression HER-2 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	trastuzumab + pertuzumab Sensitive: C3 – Early Trials	trastuzumab + pertuzumab Sensitive: C3 – Early Trials
ERCC1 negative ERCC1 negative	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	ERCC1 negative ERCC1 negative	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	SOX Sensitive: C3 – Early Trials	SOX Sensitive: C3 – Early Trials
HER-2 positive HER-2 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	HER-2 positive HER-2 positive	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	nivolumab + trastuzumab Sensitive: C3 – Early Trials	nivolumab + trastuzumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	PD-L1 overexpression PD-L1 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	durvalumab Sensitive: C3 – Early Trials	durvalumab Sensitive: C3 – Early Trials
MSI-H/dMMR + MLH1 deletion + PMS2 deletion MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	MSI-H/dMMR + MLH1 deletion + PMS2 deletion MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies	pembrolizumab Sensitive: C4 – Case Studies
TP53 mutation TP53 mutation	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	TP53 mutation TP53 mutation	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	APR-246 Sensitive: D – Preclinical	APR-246 Sensitive: D – Preclinical

Esophageal Adenocarcinoma

Associations(29)

Associations
(29)